Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioVie Inc. BIVI

Healthcare  —  Biotechnology
1.61 0.00 0.00% as of 25 Sep
Market cap
$13.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

BioVie Inc. (BIVI) Business Profile

Updated before January 2025

Company Overview

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company focused on developing innovative therapies for chronic debilitating conditions. Founded in 2013, the company is headquartered in Carson City, Nevada, with additional operational facilities in other strategic locations. BioVie’s mission is to address unmet medical needs in areas such as neurodegenerative diseases, liver diseases, and other chronic conditions. The company is led by a team of seasoned professionals, including its CEO, Cuong V. Do, who brings extensive experience in healthcare and biotechnology. The leadership team is supported by a board of directors and scientific advisors with deep expertise in drug development and commercialization.

Core Business Segments

Neurological Disorders

BioVie’s primary focus is on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease and Parkinson’s disease. The company’s lead product candidate, NE3107, is an oral small molecule targeting neuroinflammation and insulin resistance, both of which are believed to play critical roles in the progression of Alzheimer’s and Parkinson’s diseases. NE3107 is currently in advanced clinical trials and has shown promising results in improving cognitive and motor functions.

Liver Diseases

Another key area of focus for BioVie is liver diseases, specifically ascites, a condition characterized by the accumulation of fluid in the abdominal cavity. The company is developing BIV201, a continuous infusion therapy designed to improve the quality of life for patients suffering from refractory ascites due to advanced liver cirrhosis. BIV201 has received Orphan Drug Designation from the FDA, highlighting its potential to address a significant unmet medical need.

Other Chronic Conditions

BioVie is also exploring treatments for other chronic conditions that involve inflammation and metabolic dysfunction. The company’s pipeline includes early-stage research into therapies that could address a broader range of diseases, leveraging its expertise in targeting inflammation and insulin resistance.

Business Model

BioVie operates as a clinical-stage biotechnology company, focusing on the research, development, and commercialization of novel therapies. The company’s business model is centered around advancing its drug candidates through clinical trials, obtaining regulatory approvals, and eventually partnering with larger pharmaceutical companies for commercialization. Revenue generation is expected to come from licensing agreements, milestone payments, and royalties once its products reach the market. BioVie also actively seeks grants and funding opportunities to support its research and development activities.

Strategic Direction

BioVie’s strategic direction is focused on advancing its clinical pipeline and expanding its therapeutic areas. The company aims to:

  • Achieve Regulatory Approvals: BioVie is prioritizing the completion of clinical trials for NE3107 and BIV201, with the goal of obtaining FDA approval and bringing these therapies to market.
  • Expand Pipeline: The company is investing in research to identify new drug candidates that target inflammation and metabolic dysfunction, potentially expanding into additional therapeutic areas.
  • Forge Strategic Partnerships: BioVie plans to collaborate with larger pharmaceutical companies to leverage their commercialization expertise and global reach.
  • Sustainability Goals: While not a primary focus, BioVie is committed to conducting its operations in an environmentally responsible manner, minimizing waste, and optimizing resource use.

Competitive Landscape

BioVie operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and other clinical-stage biotechs. Key competitors include:

  • Biogen (NASDAQ: BIIB): A leader in neurodegenerative disease treatments, particularly Alzheimer’s disease.
  • Eli Lilly (NYSE: LLY): Known for its innovative therapies in Alzheimer’s and other chronic conditions.
  • Intercept Pharmaceuticals (NASDAQ: ICPT): Focused on liver diseases, including treatments for cirrhosis and related conditions.
  • Smaller Biotechs: Companies like Cassava Sciences and Anavex Life Sciences are also developing therapies for Alzheimer’s and other neurodegenerative diseases.

BioVie differentiates itself through its unique approach to targeting neuroinflammation and insulin resistance, as well as its focus on refractory ascites, an area with limited treatment options.

Risk Factors

Like any clinical-stage biotechnology company, BioVie faces several risks, including:

  • Regulatory Risks: The success of BioVie’s drug candidates depends on obtaining FDA and other regulatory approvals, which are not guaranteed.
  • Clinical Trial Risks: There is always a risk that clinical trials may not demonstrate the safety and efficacy required for approval.
  • Market Dependence: BioVie’s future revenue is heavily dependent on the success of its lead candidates, NE3107 and BIV201.
  • Competition: The biotechnology sector is highly competitive, and BioVie faces the risk of being outpaced by competitors with more resources.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain issues.

Recent Developments

BioVie has made significant progress in advancing its clinical pipeline. Recent developments include:

  • NE3107 Clinical Trials: The company announced positive interim results from its Phase 3 trial for NE3107 in Alzheimer’s disease, showing improvements in cognitive and motor functions.
  • BIV201 Progress: BioVie has completed Phase 2 trials for BIV201 and is preparing for Phase 3 studies, bringing it closer to potential FDA approval.
  • Funding and Partnerships: The company recently secured additional funding to support its clinical programs and is in discussions with potential partners for commercialization.
  • Global Developments: The COVID-19 pandemic initially posed challenges for clinical trial enrollment, but BioVie has since adapted its operations to mitigate these impacts.

Investment Considerations

Strengths

  • Innovative Pipeline: BioVie’s focus on neuroinflammation and insulin resistance sets it apart from competitors.
  • Orphan Drug Designation: BIV201’s designation provides market exclusivity and potential tax benefits.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.

Risks

  • Early-Stage Company: As a clinical-stage biotech, BioVie has no approved products and is not yet generating revenue.
  • High Dependence on Lead Candidates: The company’s future success hinges on the approval and commercialization of NE3107 and BIV201.
  • Market Volatility: Biotechnology stocks are often subject to significant market fluctuations.

Conclusion

BioVie Inc. is a promising clinical-stage biotechnology company with a focus on addressing unmet medical needs in neurodegenerative and liver diseases. While the company faces the inherent risks of early-stage drug development, its innovative pipeline, experienced leadership, and strategic focus position it well for future growth. Investors should weigh the potential rewards against the risks, keeping an eye on upcoming clinical trial results and regulatory milestones.